17p Deletion Fish Cancer Screening Test

What is a 17p deletion fish cancer screening test?

The 17p deletion fish (fluorescence in situ hybridization) cancer screening test is a diagnostic tool used to detect a specific genetic abnormality in cancer cells, particularly in patients with chronic lymphocytic leukemia (CLL).

CLL is a type of cancer that affects the blood and bone marrow, and is primarily characterized by the excessive production of lymphocytes, a type of white blood cell. One of the key genetic abnormalities found in CLL cells is the deletion of part of a chromosome called 17p. This deletion is associated with a poor prognosis and resistance to certain treatments.

The 17p deletion fish test works by using fluorescent probes to label specific regions of the chromosomes in a patient's cancer cells. The probes are designed to bind to the deleted region of chromosome 17, and if there is a deletion present, the test will show a loss of fluorescence in that region.

This test provides valuable information to oncologists as it helps to determine the appropriate course of treatment for patients with CLL who have the 17p deletion. Patients with the deletion are typically less responsive to traditional chemotherapy and may require alternative treatments, such as targeted therapies or stem cell transplantation.

In summary, the 17p deletion fish cancer screening test is a highly precise and effective tool that enables oncologists to make more informed decisions about the treatment of patients with CLL who have this specific genetic abnormality.

What type of cancer is typically screened with a 17p deletion fish cancer screening test in ?

A 17p deletion FISH cancer screening test is typically used to screen for Chronic Lymphocytic Leukemia (CLL). CLL is a type of cancer that affects the white blood cells and is commonly found in adults above 50 years of age. The 17p deletion is a genetic abnormality that is commonly found in patients with CLL, which leads to the inactivation of a tumor suppressor gene, TP53. TP53 is responsible for controlling cell growth and division, and its inactivation can lead to uncontrolled cell growth and the development of cancer.

The FISH (Fluorescent In Situ Hybridization) test is a type of genetic test that is used to detect specific genetic abnormalities in cells. In the case of CLL, the FISH test is used to detect the 17p deletion abnormality in the patient's white blood cells. This test is often used in conjunction with other diagnostic tests, such as blood tests and physical examinations, to confirm a diagnosis of CLL.

It is important to note that a 17p deletion FISH cancer screening test is not a definitive diagnosis for CLL, but rather a screening tool to identify patients who may be at a higher risk of developing the disease. If the FISH test results are positive for the 17p deletion abnormality, further diagnostic tests may be required to confirm the diagnosis.

In summary, a 17p deletion FISH cancer screening test is typically used to screen for Chronic Lymphocytic Leukemia (CLL), a type of cancer that affects the white blood cells and is commonly found in adults above 50 years of age. The test detects the 17p deletion genetic abnormality, which is commonly found in patients with CLL and leads to the inactivation of a tumor suppressor gene, TP53. The FISH test is a reliable tool used in conjunction with other diagnostic tests to confirm a diagnosis of CLL.

Oncologists rely on the 17p deletion FISH cancer screening test to make informed decisions about the appropriate course of treatment for patients with CLL who have genetic abnormality. Patients who test positive for the 17p deletion abnormality are typically less responsive to traditional chemotherapy and may require alternative treatments, such as targeted therapies or stem cell transplantation. The precision and effectiveness of the FISH test have made it an essential tool in the diagnosis and treatment of CLL, providing patients with a better chance of successful treatment outcomes.

How is a 17p deletion fish cancer screening test performed in ?

A 17p deletion fish cancer screening test is performed to detect the presence of a specific genetic abnormality associated with certain forms of cancer. This test is typically used in the diagnosis and management of chronic lymphocytic leukemia (CLL), a type of blood cancer.

The test is performed using a technique known as fluorescence in situ hybridization (FISH). This technique involves the use of fluorescent probes that bind to specific DNA sequences within the cancer cells. In the case of a 17p deletion FISH test, the probe is designed to bind to the short arm of chromosome 17.

To perform the test, a sample of the patient's blood or bone marrow is obtained and sent to a laboratory for analysis. In the lab, the sample is processed to isolate the cancer cells and spread them out on a slide. The fluorescent probe is then added to the slide and allowed to bind to the targeted DNA sequences.

Under a microscope, the cancer cells can then be visualized and analyzed for the presence of the 17p deletion abnormality. If the abnormality is present, it indicates a higher risk of the cancer being resistant to certain types of treatment, and may affect the course of treatment chosen by the patient's healthcare provider.

In summary, a 17p deletion FISH cancer screening test is performed using fluorescent probes to detect a specific genetic abnormality in cancer cells. This test can be an important tool in the diagnosis and management of certain types of cancer, particularly chronic lymphocytic leukemia. By identifying patients with the 17p deletion abnormality, healthcare providers can choose alternative treatments or therapies that may provide better outcomes for these patients.

The precision and accuracy of the FISH test make it a valuable tool for oncologists and hematologists in the diagnosis and treatment of cancer, helping to ensure that patients receive personalized care based on their individual genetic makeup. As research in this area continues to evolve, it is likely that FISH testing will become even more sophisticated, offering even greater insights into the molecular basis of cancer and enabling more targeted, effective treatments for patients.

How accurate is a 17p deletion fish cancer screening test in ?

The 17p deletion fish cancer screening test is a reliable and accurate tool for detecting certain types of cancer. This test is performed by analyzing the chromosomes in cancer cells to determine whether there is a deletion in the 17p region. This deletion is associated with a higher risk of cancer recurrence and poorer prognosis in certain types of cancer, including chronic lymphocytic leukemia (CLL) and multiple myeloma.

Research has shown that the 17p deletion fish test has high sensitivity and specificity for detecting this deletion in cancer cells. Sensitivity refers to the ability of the test to correctly identify patients who have the deletion, while specificity refers to the ability of the test to correctly identify patients who do not have the deletion.

In one study of patients with CLL, the 17p deletion fish test had a sensitivity of 92% and a specificity of 99%. In another study of patients with multiple myeloma, the 17p deletion fish test had a sensitivity of 81% and a specificity of 99%. These results demonstrate the accuracy and reliability of the 17p deletion fish test for detecting this important genetic abnormality in cancer cells.

However, it is important to note that the 17p deletion fish test is just one tool in the screening and diagnosis of cancer. Other tests, such as blood tests or imaging studies, may also be necessary to fully evaluate a patient's cancer risk and determine the best course of treatment. Additionally, while the 17p deletion is associated with a higher risk of cancer recurrence and poorer prognosis, not all patients with this deletion will necessarily develop cancer. It is important for patients to work closely with their healthcare providers to understand their individual risk factors and develop a personalized care plan.

In conclusion, the 17p deletion fish cancer screening test is a valuable tool for oncologists and hematologists in the diagnosis and treatment of certain types of cancer, including CLL and multiple myeloma. With its high sensitivity and specificity, this test can help identify patients who are at a higher risk of cancer recurrence and may benefit from more aggressive treatment. As with any diagnostic tool, it is important for patients to work closely with their healthcare providers to understand the results of the test and develop an appropriate care plan. As research in this area continues to evolve, we can expect even more sophisticated testing and targeted treatments to emerge, helping to improve outcomes for cancer patients.

What is the cost of a 17p deletion fish cancer screening test in ?

The 17p deletion fish cancer screening test is an important diagnostic tool that helps in detecting certain types of cancer, such as chronic lymphocytic leukemia (CLL) and multiple myeloma. This test is performed using a technique called Fluorescence in situ hybridization (FISH), which analyzes the DNA in a patient's blood sample for the presence of a specific genetic abnormality known as 17p deletion.

The cost of the 17p deletion fish cancer screening test cost in may vary depending on a variety of factors, such as the location of the testing facility, the specific laboratory used to perform the test, and the type of insurance coverage the patient has. In general, the cost of the test can range from several hundred to several thousand dollars.

It is important to note that some insurance plans may cover the cost of the 17p deletion fish cancer screening test, while others may not. Patients are advised to check with their insurance provider to verify their coverage before undergoing the test.

In conclusion, the cost of the 17p deletion fish cancer screening test can vary depending on a variety of factors. Patients are encouraged to discuss their options with their healthcare provider and insurance provider to determine the best course of action for their specific situation.

How long does it take to get the results of a 17p deletion fish cancer screening test in ?

The 17p deletion fish cancer screening test is a highly specialized genetic test used to detect the presence of certain types of cancer, such as chronic lymphocytic leukemia (CLL). This test typically takes between 24-48 hours to produce results, depending on the specific laboratory and testing procedures being used.

The process of conducting the 17p deletion fish cancer screening test involves extracting a small amount of DNA from a patient's blood or bone marrow sample. This DNA is then analyzed using fluorescent probes that are specific to the genetic mutation being tested for (in this case, the 17p deletion). If the fluorescent probes bind to the targeted section of DNA, it indicates the presence of the mutation and a positive result for the test.

While the testing process itself may only take a day or two, it is important to note that the interpretation of the test results requires specialized knowledge and expertise in the field of oncology. A trained medical professional, such as a hematologist or oncologist, will need to review the results and provide guidance on any necessary follow-up testing or treatment.

In summary, the 17p deletion fish cancer screening test typically takes between 24-48 hours to produce results, but the interpretation of those results requires specialized expertise and should be conducted by a trained medical professional.

How often is a 17p deletion fish cancer screening test recommended in ?

The 17p deletion fish cancer screening test is commonly used to detect a specific genetic mutation that is associated with certain types of cancer. This test is particularly useful for individuals who have a family history of cancer or who may be at increased risk for developing cancer due to other factors.

The frequency with which this test is recommended can vary depending on the individual's specific circumstances. In general, individuals who are known to carry the 17p deletion mutation may be advised to undergo regular screening to monitor for the development of cancer.

For example, individuals with chronic lymphocytic leukemia (CLL) who have the 17p deletion mutation may be advised to undergo screening every 6-12 months to monitor for disease progression. Similarly, individuals with other types of cancer who carry this mutation may be advised to undergo regular screening to monitor for the development of new tumors.

It is important to note that the frequency of screening will be determined by a healthcare provider based on a thorough evaluation of the individual's medical history, risk factors, and other relevant factors. As such, individuals who are concerned about their risk for cancer or who have a family history of cancer should speak to their healthcare provider to determine whether they may benefit from 17p deletion fish cancer screening and how often such screening should be performed.

DESCRIPTION – chromosome 17p deletion involves the p53 tumor suppression gene. Its product normally prevents cells having damaged DNA from progressing from the G1 to the S phase in the cell cycle.

CLINICAL UTILITY – this test is used to detect the deletion (loss of heterozygosity) of the tumor suppressor gene TP53, which can be seen in plasma cell myeloma or CLL.

METHODOLOGY – fluorescence in situ hybridization (FISH)
TURN AROUND TIME – 7 days
PATIENT PREPARATION –
COLLECT – non diluted bone marrow aspirate or sodium heparin
SPECIMEN PREPARATION – 3-4 ml bone marrow or peripheral blood in green top (sodium heparin) or lavender top (EDTA) tube
STORAGE/TRANSPORT TEMPERATURE – room temperature
STABILITY – ambient: 48 hours; refrigerated: 48 hours
UNACCEPTABLE CONDITIONS – frozen and clotted specimens
MRP – 3500.00
SPECIAL INSTRUCTIONS – clinical history is mandatory